Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
出版年份 2021 全文链接
标题
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 7, Pages 946-958
出版商
Elsevier BV
发表日期
2021-06-16
DOI
10.1016/s1470-2045(21)00241-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
- (2021) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
- (2020) Praful Ravi et al. JAMA Oncology
- Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
- (2020) Anita Gul et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma
- (2017) Chengkuan Cai et al. Experimental and Therapeutic Medicine
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now